The present analyses, however, show that vadadustat provides regulated, limited inductions of endogenous EPO, improves iron availability, and represents a safe, effective alternative to the current treatment of patients with anemia and DD‐CKD, including patients requiring high ESA doses. The gene discussed is EPO; the disease is chronic kidney disease.